Wegovy vs Ozempic UK - Compare Prices & Cheapest Option

Clinically Proven UK Registered Pharmacy

Wegovy vs Ozempic - Compare Prices & Cheapest UK Option

Compare Wegovy and Ozempic at the cheapest UK price from £69.00 — Save £20 off with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £69.00

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Wegovy vs Ozempic: Clinical Differences, UK Pricing & Which Semaglutide Works Best for Weight Loss

The wegovy vs ozempic debate confuses many UK patients seeking semaglutide treatment, yet these medications share the same active ingredient but serve fundamentally different licensed purposes. Wegovy is licensed specifically for chronic weight management at higher therapeutic doses, whilst Ozempic is licensed for type 2 diabetes at lower doses — though both contain semaglutide, a GLP-1 receptor agonist proven to reduce appetite and improve glycaemic control. Understanding the clinical distinctions, dosing protocols, and UK pricing structures is essential before starting treatment, as prescribing decisions depend on your medical history and weight loss goals.

What Is the Core Difference Between Wegovy vs Ozempic?

The fundamental distinction in the wegovy vs ozempic comparison lies in licensing and therapeutic dosing, not chemical composition. Both medications contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics natural gut hormones to suppress appetite and slow gastric emptying [1]. Ozempic received MHRA approval in 2018 for type 2 diabetes management at maintenance doses of 0.5mg, 1mg, or 2mg weekly, with weight loss observed as a beneficial side effect during clinical trials. Wegovy gained UK approval in 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27), using a higher maximum dose of 2.4mg weekly [2].

This licensing difference matters clinically because UK prescribers must follow MHRA-approved indications when issuing prescriptions. Ozempic cannot legally be prescribed solely for weight loss in non-diabetic patients, though some clinics historically offered off-label use before Wegovy's availability. The STEP clinical trial programme demonstrated that semaglutide 2.4mg (Wegovy's dose) produced average weight loss of 15-17% body weight over 68 weeks, significantly higher than the 5-10% observed with Ozempic's diabetes-focused doses [2]. Patients seeking weight management should therefore request Wegovy through proper clinical assessment, whilst those with type 2 diabetes benefit from Ozempic's glucose-lowering effects alongside modest weight reduction.

Wegovy vs Ozempic Dosing Schedules: How Treatment Protocols Differ

The wegovy vs ozempic dosing comparison reveals distinct titration schedules designed for different therapeutic goals. Wegovy follows a gradual 16-20 week escalation protocol starting at 0.25mg weekly, increasing monthly through 0.5mg, 1mg, 1.7mg, and finally reaching the maintenance dose of 2.4mg weekly [1]. This extended titration minimises gastrointestinal side effects — particularly nausea and vomiting — which affect approximately 44% of patients during dose increases but typically resolve within 4-8 weeks as tolerance develops. The higher final dose maximises GLP-1 receptor activation for appetite suppression and sustained weight loss.

Ozempic's titration is faster and targets lower maintenance doses: patients begin at 0.25mg weekly for four weeks, then increase to 0.5mg or 1mg depending on glycaemic control needs, with 2mg available for those requiring additional HbA1c reduction [2]. Most diabetic patients remain on 0.5mg or 1mg long-term, doses shown in SUSTAIN trials to reduce HbA1c by 1.5-1.8% whilst producing 4-6kg average weight loss over 30 weeks. The key clinical implication is that Wegovy's higher dose delivers substantially greater weight reduction — approximately 12-15kg average loss versus 4-6kg with standard Ozempic doses — making direct comparison of outcomes between the two medications misleading unless dose equivalence is considered.

Injection Technique and Pen Devices

Both Wegovy and Ozempic use pre-filled subcutaneous injection pens administered once weekly, with identical injection technique into the abdomen, thigh, or upper arm. The primary difference lies in pen design: Ozempic pens contain four doses per pen (one month's supply at most doses), whilst Wegovy uses single-dose disposable pens for each weekly injection. Patients often find Wegovy's single-dose system simpler for dose escalation, as each pen is colour-coded for its specific strength, reducing dosing errors during titration. Both devices feature hidden needles and audible clicks to confirm dose delivery, making self-administration straightforward after initial training from a healthcare professional.

Clinical Efficacy: Wegovy vs Ozempic Weight Loss Results from Trials

When comparing wegovy vs ozempic for weight loss efficacy, clinical trial data demonstrates dose-dependent outcomes that favour Wegovy's higher semaglutide concentration. The landmark STEP 1 trial evaluated Wegovy 2.4mg in 1,961 adults with obesity, reporting average weight loss of 14.9% body weight (approximately 15.3kg) at 68 weeks versus 2.4% with placebo [2]. Notably, 86% of Wegovy participants achieved at least 5% weight loss, whilst 69% reached 10% reduction and 50% lost 15% or more — thresholds associated with significant improvements in cardiovascular risk factors, joint pain, and metabolic health markers.

Ozempic's weight loss data comes primarily from SUSTAIN trials designed for diabetes management, where weight reduction was a secondary endpoint. SUSTAIN 6 showed average weight loss of 4.3kg with 1mg Ozempic over 104 weeks in diabetic patients, whilst the 2mg dose (approved later) produced approximately 6kg average reduction [1]. These outcomes, though clinically meaningful for diabetic patients, represent roughly one-third to one-half the weight loss achieved with Wegovy's 2.4mg dose in dedicated obesity trials. The wegovy vs ozempic efficacy gap narrows when comparing Ozempic 2mg to Wegovy 1.7mg, but Wegovy's full 2.4mg maintenance dose remains the most effective semaglutide option for weight management based on current evidence.

Feature Wegovy Ozempic
Active Ingredient Semaglutide Semaglutide
Licensed Indication Chronic weight management Type 2 diabetes
Maximum Dose 2.4mg weekly 2mg weekly
Average Weight Loss 14.9% body weight (15.3kg) 4-6kg at 0.5-1mg doses
Titration Duration 16-20 weeks 4-8 weeks
Pen Type Single-dose disposable Multi-dose (4 doses per pen)
Starting Price (Cured) From £89.00 Diabetes indication only
Clinical Trial STEP programme SUSTAIN programme
NHS Availability Specialist services only Type 2 diabetes only
Nausea Incidence 44% 20-30%

Wegovy vs Ozempic UK Pricing: Cost Comparison and Value Analysis

UK pricing represents a critical factor in the wegovy vs ozempic decision for patients funding treatment privately, as NHS prescription access remains limited for weight management medications. At Cured Pharmacy, Wegovy is available from £69.00 per month following clinical assessment by our UK-registered prescribers, with transparent pricing displayed before consultation. New patients receive £20 off their first order using code Weightlossnew, reducing initial costs to £69.00 for the first month's supply. This competitive UK pricing includes the medication, clinical consultation, and discreet next-day delivery, with no hidden fees or subscription requirements.

Ozempic pricing in the UK varies by dose and supply source, though it's important to note that legitimate UK pharmacies should only dispense Ozempic for licensed type 2 diabetes indications, not solely for weight loss in non-diabetic patients. The cost-effectiveness calculation for wegovy vs ozempic depends on therapeutic goals: patients seeking maximum weight loss benefit from Wegovy's higher dose despite potentially higher per-pen costs, whilst diabetic patients requiring glucose control may find Ozempic more appropriate clinically regardless of price. Cured Pharmacy's transparent pricing model eliminates the need to compare multiple suppliers — our GPhC-registered team (registration 9012511) ensures you receive genuine UK-licensed medication at guaranteed lowest UK prices, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all clinical services.

Insurance and NHS Availability

NHS England currently restricts Wegovy prescribing to specialist weight management services in limited areas, with most patients unable to access NHS-funded treatment despite meeting clinical criteria. Ozempic faces similar NHS restrictions, officially available only for type 2 diabetes when other treatments prove insufficient, though recent shortages have further limited availability. Private prescription through registered UK pharmacies like Cured remains the most reliable access route for both medications, with clinical assessment ensuring appropriate prescribing aligned with MHRA guidelines. Some private health insurance policies cover GLP-1 medications when prescribed for licensed indications, though coverage varies significantly between providers and typically requires prior authorisation from your insurer.

Side Effects Profile: Wegovy vs Ozempic Safety Comparison

The wegovy vs ozempic side effects profile is nearly identical due to shared active ingredient semaglutide, with adverse event frequency correlating to dose intensity. Gastrointestinal symptoms dominate both medications' safety data: nausea affects 44% of Wegovy users and 20-30% of Ozempic users, whilst vomiting, diarrhoea, and constipation occur in 15-30% of patients across both treatments [1]. These effects typically peak during dose escalation, diminish within 4-8 weeks as physiological tolerance develops, and can be minimised through gradual titration and dietary modifications such as smaller meal portions and reduced fatty food intake.

Serious adverse events remain rare but consistent across semaglutide formulations, including pancreatitis risk (0.2-0.3% incidence), gallbladder disorders related to rapid weight loss, and theoretical thyroid C-cell tumour risk observed in rodent studies but not confirmed in human populations [2]. Both Wegovy and Ozempic carry contraindications for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. The primary safety distinction in the wegovy vs ozempic comparison relates to dose-dependent intensity: Wegovy's 2.4mg dose produces slightly higher rates of gastrointestinal side effects compared to Ozempic's 0.5-1mg doses, though discontinuation rates due to adverse events remain similar at 5-7% across clinical trials. UK prescribers assess individual risk factors during consultation to determine the most appropriate semaglutide option for each patient's medical history.

Which Should You Choose? Wegovy vs Ozempic Decision Framework

The wegovy vs ozempic choice depends primarily on your clinical indication and treatment goals rather than personal preference alone. Patients with type 2 diabetes seeking improved glycaemic control alongside moderate weight loss should request Ozempic, as its licensed indication aligns with diabetes management and clinical trials demonstrate significant HbA1c reductions of 1.5-1.8% alongside 4-6kg average weight loss [2]. Non-diabetic individuals with obesity (BMI ≥30) or overweight with weight-related comorbidities (BMI ≥27 with hypertension, dyslipidaemia, or obstructive sleep apnoea) should pursue Wegovy, which offers higher-dose semaglutide specifically licensed and optimised for chronic weight management.

Practical considerations also influence the wegovy vs ozempic decision for UK patients accessing private treatment. Wegovy's single-dose pen system simplifies weekly injections and reduces dosing errors during titration, whilst its dedicated weight loss licensing ensures prescribing aligns with MHRA regulations. Ozempic's multi-dose pen may appeal to some patients for convenience, though prescribers must confirm appropriate diabetic indication before issuing prescriptions. Cost differences between the medications at equivalent doses are typically minimal when sourced from registered UK pharmacies, making clinical appropriateness rather than price the primary decision factor. Cured Pharmacy's clinical team conducts thorough assessments to recommend the most suitable semaglutide option based on your medical history, current medications, weight loss goals, and any diabetic status — ensuring safe, effective treatment aligned with UK prescribing standards.

Starting Your Assessment at Cured Pharmacy

Beginning treatment requires completing a confidential online clinical assessment reviewed by our UK-registered prescribers, typically taking under three minutes. The assessment captures your medical history, current medications, weight and height measurements, and any contraindications to semaglutide therapy. Our clinical team evaluates your suitability for either Wegovy or Ozempic based on licensed indications, recommending the most appropriate option or suggesting alternative weight loss treatments if semaglutide proves unsuitable. Approved prescriptions are dispensed the same day from our GPhC-registered pharmacy, with discreet next-day delivery ensuring prompt treatment initiation. All services include ongoing clinical support, with our pharmacist team available via phone (+44 116 4646009) for questions about injection technique, side effect management, or dose adjustments throughout your treatment journey.

Scientific References

  1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
  3. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  4. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  5. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can I switch from Ozempic to Wegovy for better weight loss results?
Yes, patients currently using Ozempic off-label for weight loss can transition to Wegovy under prescriber guidance, typically continuing at their current Ozempic dose before escalating to Wegovy's 2.4mg maintenance dose. The wegovy vs ozempic transition requires clinical assessment to confirm appropriate licensing and dosing protocol.
Is Wegovy or Ozempic better for weight loss in the UK?
Wegovy demonstrates superior weight loss outcomes due to its higher 2.4mg semaglutide dose, producing average 14.9% body weight reduction versus 4-6kg with standard Ozempic doses in clinical trials. Wegovy is also specifically licensed for weight management, making it the clinically appropriate choice for non-diabetic patients seeking weight loss.
Why is Ozempic cheaper than Wegovy in some UK pharmacies?
Pricing variations often reflect dose differences and pen formats rather than medication quality — Ozempic's multi-dose pens and lower typical doses may reduce per-month costs, though legitimate UK pharmacies should only dispense Ozempic for licensed diabetes indications. When comparing wegovy vs ozempic pricing, consider total treatment cost including clinical appropriateness and expected outcomes.
Do Wegovy and Ozempic have the same side effects?
Yes, both medications share identical side effect profiles as they contain the same active ingredient semaglutide, with nausea, vomiting, and diarrhoea being most common. Wegovy's higher dose produces slightly increased gastrointestinal symptom frequency (44% vs 20-30% nausea rates), though severity and duration remain comparable between the two treatments.
Can I use Ozempic for weight loss if I don't have diabetes?
UK prescribers should not prescribe Ozempic solely for weight loss in non-diabetic patients, as it is licensed only for type 2 diabetes management. Wegovy is the appropriate semaglutide formulation for weight management in patients without diabetes, carrying proper MHRA licensing for obesity treatment.
How long does it take to see results with Wegovy vs Ozempic?
Most patients notice appetite reduction within 1-2 weeks of starting either medication, with measurable weight loss typically beginning after 4-8 weeks once therapeutic doses are reached. The wegovy vs ozempic timeline differs slightly due to dosing schedules, with Wegovy requiring 16-20 weeks to reach maximum 2.4mg dose versus 4-8 weeks for Ozempic's lower maintenance doses.
Will I regain weight after stopping Wegovy or Ozempic?
Clinical trial data shows most patients regain 60-70% of lost weight within one year of discontinuing semaglutide treatment, as the medication's appetite-suppressing effects cease when injections stop. Both Wegovy and Ozempic are intended as long-term chronic treatments combined with lifestyle modifications to maintain weight loss results.
Can I get Wegovy or Ozempic on the NHS for weight loss?
NHS access to Wegovy remains extremely limited, available only through specialist weight management services in select areas with long waiting lists. Ozempic is not funded by NHS for weight loss in non-diabetic patients. Most UK patients seeking semaglutide for weight management access treatment through private prescription from registered pharmacies like Cured.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.